The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients
https://doi.org/10.34215/1609-1175-2020-3-5-10
Abstract
Today, glaucoma is considered to be the most common cause of irreversible blindness. The treatment of this disease is aimed at reducing intraocular tension in order to slow down the deterioration of visual functions and to maintain accept‑ able quality of life. Most ophthalmologists prefer local medicamentous therapy. Despite a significant expansion of the range of antihypertensive medicines, a significant increase in the hypotensive effect is not always achieved in each certain case, at the same time, at long-term (sometimes lifetime) treatment local and systemic adverse reactions arise and intensify. The findings of recent clinical trials presented in this overview demonstrate an adverse effect of active compounds, preservatives and ad‑ ditives of ophthalmic medicines not only on the eye surface but also on the structure of anterior and posterior eye segments. Taking into account possible side effects of each component of medicines used in glaucoma therapy, ophthalmologists will be able to reasonably approach the choice of optimal treatment regimens with the lowest risk for patients.
About the Authors
O. N. Onufriichuk
H. Turner National Medical Research Center for Сhildren’s Orthopedics and Trauma Surgery
Russian Federation
Russian Federation
MD, PhD,
64–68 Parkovaya St., Pushkin, Saint Petersburg, 196603
I. R. Gazizova
Institute of Experimental Medicine
Russian Federation
Russian Federation
MD, PhD, head of the Ophthalmology Department,
12 Akademika Pavlova St., Saint Petersburg, 197376
A. V. Kuroyedov
Mandryka Central Clinical Hospital;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
head of the Ophthalmology Department, 8a B. Olenya St., Moscow, 107014;
MD, PhD, professor, 1 Ostrovityanova St., Moscow, 117997
A. V. Seleznev
State Medical Academy
Russian Federation
Russian Federation
MD, PhD, associate professor,
8 Sheremetevskii Ave., Ivanovo, 153012
References
1. Federalnyi zakon ot 12.04.2010 No. 61-FZ (red. ot 27.12.2018) “Ob obrashchenii lekarstvennykh sredstv” (In Russ).
2. Petrov SYu, Safonova DM. Ophthalmic preservatives: From benzalkonium chloride to polyquaternium. Literature review. RMZh. Klinicheskaya oftalmologiya. 2014;14(2):97–108 (In Russ).
3. Trzeciecka A, Paterno JJ, Toropainen E, Koskela A, Podracka L., Korhonen E, et al. Long-term topical application of preservativefree prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur J Pharmacol. 2016;788:12–20.
4. Lee S, Kim MK, Choi HJ, Wee WR, Kim DM. Comparative crosssectional analysis of the effects of topical antiglaucoma drugs on the ocular surface. Adv Therapy. 2013;30(4):420–9.
5. Smedowski A, Paterno JJ, Toropainen E, Toropainen E, Sinha D, Wylegala D, Kaarniranta K. Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. J Biochem Pharmacol Res. 2014;2(4):175–84.
6. Pinheiro R, Panfil C, Schrage N, Dutescu RM. The impact of glaucoma medications on corneal wound healing. J Glaucoma. 2016;25(1):122–7.
7. Alekseev IB, Melnikova NV. Changes of the anterior surface of the eye in primary open angle glaucoma. Rossiiskii oftalmologicheskii zhurnal. 2013;6(1):4–7 (In Russ).
8. Petrov SYu. Tafluprost – a novel prostaglandin F2α analogue. Vestnik oftalmologii. 2014;130(5):85–95 (In Russ).
9. Klimko PG, Sharif NA. Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol. 2018;176(8):1051–8.
10. Yang Y, Huang C, Lin X, Wu Y, Ouyang W, Tang L, et al. 0.005% preservative-free Latanoprost induces dry eye-like ocular surface damage via promotion of inflammation in mice. Invest Ophthalmol Vis Sci. 2018;59(8):3375–84.
11. Martinez-de-la-Casa JM, Perez-Bartolome F, Urcelay E, Santiago JL, Moreno-Montañes J, Arriola-Villalobos P, et al. Tear cytokine profile of glaucoma patients treated with preservativefree or preserved Latanoprost. Ocul Surf. 2017;15(4):723–9.
12. Tokuda N, Kitaoka Y, Matsuzawa A, Tsukamoto A, Sase K, Sakae S, Takagi H. Changes in ocular surface characteristics after switching from Benzalkonium chloride-preserved Latanoprost to preservative-free Tafluprost or Benzalkonium chloridepreserved Tafluprost. J Ophthalmol. 2017;2017:3540749. doi: 10.1155/2017/3540749
13. Kim JH, Kim EJ, Kim YH, Kim YI, Lee SH, Jung JC, et al. In vivo effects of preservative-free and preserved prostaglandin analogs: Mouse ocular surface study. Korean J Ophthalmol. 2015;29(4):270–9.
14. Rolle T, Spinetta R, Nuzzi R. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: A cross sectional study. BMC Ophthalmol. 2017;17(1):136. doi: 10.1186/s12886-017-0534-z
15. Pérez-Roca F, Rodrigo-Morales E, Garzón I, Oliveira AC, MartínPiedra MÁ, Carriel V, et al. Effects of four formulations of prostaglandin analogs on eye surface cells. A comparative study. PLoS One. 2015;10(6):e0129419. doi: 10.1371/journal.pone.0129419
16. Moschos MM, Moustafa GA, Papakonstantinou VD, Tsatsos M, Laios K, Antonopoulou S. Anti-platelet effects of anti-glaucomatous eye drops: An in vitro study on human platelets. Drug Des Devel Ther. 2017;11:1267–72.
17. Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, et al. The Glaucoma Italian Pediatric Study (GIPSy): 3-year results. J Glaucoma. 2018;27(10):856–63.
18. Malikowski TM, Bosch JB, Min S, Duffey ME, Patel SP. Carbonic anhydrase inhibitors in corneal endothelial transport. Invest Ophthalmol Vis Sci. 2014;55(4):2652–8.
19. Dong Y, Sawada Y, Cui J, Hayakawa M, Ogino D, Ishikawa M, Yoshitomi T. Dorzolamide-induced relaxation of isolated rabbit ciliary arteries mediated by inhibition of extracellular calcium influx. Jpn J Ophthalmol. 2016;60(2):103–10.
20. Nakano T, Inoue R, Kimura T, Suzumura H, Tanino T, Yamazaki Y, et al. Effects of Brinzolamide, a topical carbonic anhydrase inhibitor, on corneal endothelial cells. Adv Ther. 2016;33(8):1452–9.
21. Shimazaki J, Hanada K, Yagi Y, Yamagami J, Ishioka M, Shimmura S, Tsubota K. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostone. Br J Ophthalmol. 2000;84(11):1250–4.
22. Inoue K, Okugawa K, Kato S, Inoue Y, Tomita G, Oshika T, Amano S. Ocular factors relevant to antiglaucomatous eye droprelated keratoepitheliopathy. J Glaucoma. 2003;12(6):480–5.
23. Aydin Kurna S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: A prospective study. J Ophthalmol. 2014:460483. doi: 10.1155/2014/460483
24. Li N, Shi HM, Cong L, Lu ZZ, Ye W, Zhang YY. Outflow facility efficacy of five drugs in enucleated porcine eyes by a method of constant-pressure perfusion. Int J Clin Exp Med. 2015;8(5):7184–91.
25. Hong S, Han SH, Kim CY, Kim KY, Song YK, Seong GJ. Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon’s fibroblasts. BMC Ophthalmol. 2015;15(1):54. doi: 10.1186/s12886-015-0045-8
26. Ho LC, Conner IP, Do CW, Kim SG, Wu EX, Wollstein G, et al. In vivo assessment of aqueous humor dynamics upon chronic ocular hypertension and hypotensive drug treatment using gadolinium-enhanced MRI. Invest Ophthalmol Vis Sci. 2014; 55(6):3747–57.
27. Pillunat LE, Eschstruth P, Häsemeyer S, Thelen U, Foja C., Leaback R, Pfennigsdorf S. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clin Ophthalmol. 2016;10:1759–65.
28. Clinical Review Report: Preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost): (Laboratoires Théa): Indication: Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 May. CADTH Common Drug Reviews.
29. Economou MA, Laukeland HK, Grabska-Liberek I, Rouland JF. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clin Ophthalmol. 2018;12:2399–407.
30. Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: A meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–54.
31. El Hajj Moussa WG, Farhat RG, Nehme JC, Sahyoun MA, Schakal AR, Jalkh AE, et al. Comparison of efficacy and ocular surface disease index score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in glaucoma patients. J Ophthalmol. 2018:1319628. doi: 10.1155/2018/1319628
32. Onishchenko AL, Dimaksian MV, Kolbasko AV, Zhilina NM. Preservative-free betaxolol for POAG patients: Evaluation of hypotensive effect and ocular surface safety. Vestnik oftalmologii. 2015;131(2):76–80 (in Russ).
33. Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf. 2017;16(9):1071–8.
34. Ackerman SL, Torkildsen GL, McLaurin E, Vittitow JL. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Clin Exp Optom. 2018. doi: 10.1111/cxo.12846
35. Shah AA, Modi Y, Thomas B, Wellik SR, Galor A. Brimonidine allergy presenting as vernal-like keratoconjunctivitis. J Glaucoma. 2015;24(1):89–91. ‘
36. Tsumura T, Yoshikawa K, Kimura T, Suzumura H, Kawashima M, Nanno M, et al. The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients. Clin Ophthalmol. 2014;8:1681–7.
37. Taketani Y, Yamagishi R, Fujishiro T, Igarashi M, Sakata R, Aihara M. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1269–76.
38. Miki T, Naito T, Fujiwara M, Araki R, Kiyoi R, Shiode Y, et al. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One. 2017;12(7):e0181550. doi: 10.1371/journal.pone.0181550
39. Mendonça TB, Lummertz AP, Bocaccio FJ, Procianoy F. Effect of low-concentration, nonmydriatic selective alpha-adrenergic agonist eyedrops on upper eyelid position. Dermatol Surg. 2017;43(2):270–4.
40. Yanagi M, Kiuchi Y, Yuasa Y, Yoneda T, Sumi T, Hoshikawa Y, et al. Association between glaucoma eye drops and hyperemia. Jpn J Ophthalmol. 2016;60(2):72–7.
41. Docherty JR, Steinhoff M, Lorton D, Detmar M, Schäfer G, Holmes A, Di Nardo A. Multidisciplinary consideration of potential pathophysiologic mechanisms of paradoxical erythema with topical Brimonidine therapy. Adv Ther. 2016;33(11):1885–95.
42. Lee SJ, Kim M. Allergic contact dermatitis caused by dorzolamide eyedrops. Clin Ophthalmol. 2015;9:575–7.
43. Maruyama Y, Ikeda Y, Yokoi N, Mori K, Kato H, Ueno M, et al. Severe corneal disorders developed after brimonidine tartrate ophthalmic solution use. Cornea. 2017;36(12):1567–9.
44. Энциклопедия лекарств и товаров аптечного ассортимента [Encyclopedia of medicines and pharmaceutical products (In Russ).] URL: https://www.rlsnet.ru (Accessed: 3 February 2020).
45. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet J-M, Brignole-Baudouin F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmol. 2008;115(1):109–15.
46. Lee W, Lee S, Bae H, Kim CY, Seong GJ. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study. BMC Ophthalmol. 2017;17(1):61. doi: 10.1186/s12886-017-0453-z
47. Hommer A, Schmidl D, Kromus M, Bata AM, Fondi K, Werkmeister RM, et al. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. Eur J Ophthalmol. 2018;28(4):385–92.
48. Konstas AG, Boboridis KG, Kapis P, Marinopoulos K, Voudouragkaki IC, Panayiotou D, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free Dorzolamide/Timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved Latanoprost monotherapy. Adv Ther. 2017;34(1):221–35.
49. El Ameen A, Vandermeer G, Khanna RK, Pisella PJ. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2018. doi: 10.1177/1120672118805877
50. Beltz J, Zamir E. Brimonidine induced anterior uveitis. Ocul Immunol Inflamm. 2016;24(2):128–33.
51. Young JW, Clements JL, Morrison JC, Takusagawa HL. Brinzolamide-induced follicular conjunctivitis. J Glaucoma. 2018;27(11):e183–4. doi: 10.1097/ijg.0000000000001063
52. Choi DY, Chang RT, Yegnashankaran K, Friedman NJ. Reversible conjunctival pigmentation associated with prostaglandin use. J Glaucoma. 2016;25(1):e56–7. doi: 10.1097/ijg.0000000000000255
53. Beckwith-Cohen B, Bentley E, Gasper DJ, McLellan GJ, Dubielzig RR. Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma. J Am Vet Med Assoc. 2015;247(12):1419–26.
54. Ba-Ali S, Sander B, Brøndsted AE, Lund-Andersen H. Effect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometry. Front Neurol. 2015;6:93. doi: 10.3389/ fneur.2015.00093
55. Von Zup M, Lassaline M, Kass PH, Miller PE, Thomasy SM. Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes. Equine Vet J. 2017;49(6):810–4.
56. Kato COS., Shimizu K, Kamiya K, Ishikawa H, Igarashi A. Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex. Sci Rep. 2018;8(1):9003. doi: 10.1038/s41598-018-27436-8
57. Comet A, Donnadieu B, Courjaret JC, Gascon P, Denis D, Matonti F. Brimonidine and acute anterior granulomatous uveitis: A case report and literature review. J Fr Ophtalmol. 2017;40(4):e127–9. doi: 10.1016/j.jfo.2016.01.016
Review
For citations:
Onufriichuk O.N., Gazizova I.R., Kuroyedov A.V., Seleznev A.V. The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients. Pacific Medical Journal. 2020;(3):5-10. (In Russ.) https://doi.org/10.34215/1609-1175-2020-3-5-10
Views:
557
Email this article 